Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• (Inter)nationalising the antibiotic research and development pipeline.1 passage
• 100 years of Mycobacterium bovis bacille Calmette-Guérin.1 passage
• 2018 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation.1 passage
• 30-year trends in admission rates for encephalitis in children in England and effect of improved diagnostics and measles-mumps-rubella vaccination: a population-based observational study.1 passage
• A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study.1 passage
• A blood-based host gene expression assay for early detection of respiratory viral infection: an index-cluster prospective cohort study.1 passage
• A call to strengthen the global strategy against schistosomiasis and soil-transmitted helminthiasis: the time is now.1 passage
• A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study.1 passage
• A comprehensive repertoire of prokaryotic species identified in human beings.1 passage
• A decentralised point-of-care testing model to address inequities in the COVID-19 response.1 passage
• A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study.1 passage
• A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.1 passage
• A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail.1 passage
• A governance framework for development and assessment of national action plans on antimicrobial resistance.1 passage
• A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study.1 passage
• A household-level score to predict the risk of tuberculosis among contacts of patients with tuberculosis: a derivation and external validation prospective cohort study.1 passage
• A minimal common outcome measure set for COVID-19 clinical research.1 passage
• A multimodal infection control and patient safety intervention to reduce surgical site infections in Africa: a multicentre, before-after, cohort study.1 passage
• A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study.1 passage
• A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study.1 passage
• A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.1 passage
• A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study.1 passage
• A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.1 passage
• AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial.1 passage
• Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.1 passage
• Acanthamoeba castellanii encephalitis in a patient with AIDS: a case report and literature review.1 passage
• Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia.1 passage
• Access to treatment for hepatitis C virus infection: time to put patients first.1 passage
• Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.1 passage
• Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis.1 passage
• Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue.1 passage
• Active and passive case-finding in tuberculosis-affected households in Peru: a 10-year prospective cohort study.1 passage
• Acute superior mesenteric vein thrombosis in the setting of cytomegalovirus mononucleosis: a case report and review of the literature.1 passage
• Adapting to the global shortage of cholera vaccines: targeted single dose cholera vaccine in response to an outbreak in South Sudan.1 passage
• Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.1 passage
• Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial.1 passage
• Advanced imaging tools for childhood tuberculosis: potential applications and research needs.1 passage
• Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings.1 passage
• Advancing the public health applications of Chlamydia trachomatis serology.1 passage
• Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.1 passage
• Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines.1 passage
• Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.1 passage
• Age-dependent manifestations and case definitions of paediatric Zika: a prospective cohort study.1 passage
• Alternatives to antibiotics-a pipeline portfolio review.1 passage
• An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial.1 passage
• An international outbreak of Salmonella enterica serotype Enteritidis linked to eggs from Poland: a microbiological and epidemiological study.1 passage
• An unexpected tetanus case.1 passage
• An update of the global burden of pertussis in children younger than 5 years: a modelling study.1 passage
• Analysis of blood from Zika virus-infected fetuses: a prospective case series.1 passage
• Analysis of the clinical antibacterial and antituberculosis pipeline.1 passage
• Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial.1 passage
• Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines.1 passage
• Antibiotic exposure among children younger than 5 years in low-income and middle-income countries: a cross-sectional study of nationally representative facility-based and household-based surveys.1 passage
• Antibiotic prescription for febrile children in European emergency departments: a cross-sectional, observational study.1 passage
• Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.1 passage
• Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.1 passage
• Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.1 passage
• Antibody responses to filovirus infections in humans: protective or not?1 passage
• Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.1 passage
• Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.1 passage
• Antimalarial drug resistance in Africa: the calm before the storm?1 passage
• Antimicrobial resistance among children in sub-Saharan Africa.1 passage
• Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis.1 passage
• Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review.1 passage
• Antimicrobial stewardship across 47 South African hospitals: an implementation study.1 passage
• Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group, multicentre trial.1 passage
• Application of the Third International Consensus Definitions for Sepsis (Sepsis-3) Classification: a retrospective population-based cohort study.1 passage
• Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study.1 passage
• Aquaculture as yet another environmental gateway to the development and globalisation of antimicrobial resistance.1 passage
• Aqueous olanexidine versus aqueous povidone-iodine for surgical skin antisepsis on the incidence of surgical site infections after clean-contaminated surgery: a multicentre, prospective, blinded-endpoint, randomised controlled trial.1 passage
• Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?1 passage
• Are placebo controls necessary in controlled human infection trials for vaccines?1 passage
• Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.1 passage
• Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial.1 passage
• Arthritogenic alphaviruses: epidemiological and clinical perspective on emerging arboviruses.1 passage
• Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox.1 passage
• Assessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: a metapopulation modelling study.1 passage
• Assessing the epidemiological effect of wolbachia for dengue control.1 passage
• Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical sales data.1 passage
• Assessment of blood enterovirus PCR testing in paediatric populations with fever without source, sepsis-like disease, or suspected meningitis: a prospective, multicentre, observational cohort study.1 passage
• Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.1 passage
• Assessment of global guidelines for preventive chemotherapy against schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study.1 passage
• Assessment of non-prescription antibiotic dispensing at community pharmacies in China with simulated clients: a mixed cross-sectional and longitudinal study.1 passage
• Assessment of ultra-sensitive malaria diagnosis versus standard molecular diagnostics for malaria elimination: an in-depth molecular community cross-sectional study.1 passage
• Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies.1 passage
• Association between Zika virus infection and microcephaly in Brazil, January to May, 2016: preliminary report of a case-control study.1 passage
• Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study.1 passage
• Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study.1 passage
• Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study.1 passage
• Association between spending on social protection and tuberculosis burden: a global analysis.1 passage
• Association between the proportion of Plasmodium falciparum and Plasmodium vivax infections detected by passive surveillance and the magnitude of the asymptomatic reservoir in the community: a pooled analysis of paired health facility and community data.1 passage
• Association between urinary community-acquired fluoroquinolone-resistant Escherichia coli and neighbourhood antibiotic consumption: a population-based case-control study.1 passage
• Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.1 passage
• Association of gestational age and growth measures at birth with infection-related admissions to hospital throughout childhood: a population-based, data-linkage study from Western Australia.1 passage
• Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study.1 passage
• Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus.1 passage
• Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in Switzerland.1 passage
• Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.1 passage
• Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings.1 passage
• BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.1 passage
• Barriers and enablers to implementing tuberculosis control strategies in EU and European Economic Area countries: a systematic review.1 passage
• Barriers and facilitators to the uptake of tuberculosis diagnostic and treatment services by hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review of qualitative literature.1 passage
• Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.1 passage
• Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation.1 passage
• Biodefence research two decades on: worth the investment?1 passage
• Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.1 passage
• British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases.1 passage
• Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study.1 passage
• Burden of disease in Gabon caused by loiasis: a cross-sectional survey.1 passage
• Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.1 passage
• Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study.1 passage
• Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem.1 passage
• CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.1 passage
• COVID-19 and multisystem inflammatory syndrome in children and adolescents.1 passage
• COVID-19 human challenge studies: ethical issues.1 passage
• COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study.1 passage
• Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.1 passage
• Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.1 passage
• Can we contain the COVID-19 outbreak with the same measures as for SARS?1 passage
• Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer.1 passage
• Catheter-related infections in patients with haematological malignancies: novel preventive and therapeutic strategies.1 passage
• Cavitary tuberculosis: the gateway of disease transmission.1 passage
• Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.1 passage
• Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.1 passage
• Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.1 passage
• Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.1 passage
• Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.1 passage
• Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.1 passage
• Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study.1 passage
• Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study.1 passage
• Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.1 passage
• Chains of transmission and control of Ebola virus disease in Conakry, Guinea, in 2014: an observational study.1 passage
• Challenges and key research questions for yaws eradication.1 passage
• Challenges and opportunities for the management of infectious diseases in Europes' prisons: evidence-based guidance.1 passage
• Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study.1 passage
• Changes in epilepsy burden after onchocerciasis elimination in a hyperendemic focus of western Uganda: a comparison of two population-based, cross-sectional studies.1 passage
• Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.1 passage
• Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis.1 passage
• Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study.1 passage
• Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen.1 passage
• Chlamydia trachomatis and the risk of spontaneous preterm birth, babies who are born small for gestational age, and stillbirth: a population-based cohort study.1 passage
• Chlorhexidine for meatal cleaning in reducing catheter-associated urinary tract infections: a multicentre stepped-wedge randomised controlled trial.1 passage
• Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial.1 passage
• Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.1 passage
• Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study.1 passage
• Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.1 passage
• Clinical and epidemiological performance of WHO Ebola case definitions: a systematic review and meta-analysis.1 passage
• Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.1 passage
• Clinical and virological data of the first cases of COVID-19 in Europe: a case series.1 passage
• Clinical bacteriology in low-resource settings: today's solutions.1 passage
• Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis.1 passage
• Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study.1 passage
• Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.1 passage
• Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.1 passage
• Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report.1 passage
• Clinical features for diagnosis of pneumonia in children younger than 5 years: a systematic review and meta-analysis.1 passage
• Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study.1 passage
• Clinical interventions for tungiasis (sand flea disease): a systematic review.1 passage
• Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study.1 passage
• Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study.1 passage
• Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study.1 passage
• Clinical value of whole-genome sequencing of Mycobacterium tuberculosis.1 passage
• Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.1 passage
• Community burden and transmission of acute gastroenteritis caused by norovirus and rotavirus in the Netherlands (RotaFam): a prospective household-based cohort study.1 passage
• Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.1 passage
• Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study.1 passage
• Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.1 passage
• Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study.1 passage
• Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.1 passage
• Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis.1 passage
• Comparative pathogenesis of rabies in bats and carnivores, and implications for spillover to humans.1 passage
• Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.1 passage
• Comparing accuracy of lipoarabinomannan urine tests for diagnosis of pulmonary tuberculosis in children from four African countries: a cross-sectional study.1 passage
• Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study.1 passage
• Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.1 passage
• Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study.1 passage
• Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.1 passage
• Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study.1 passage
• Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial.1 passage
• Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.1 passage
• Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis.1 passage
• Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.1 passage
• Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy.1 passage
• Congenital syphilis, the great imitator-case report and review.1 passage
• Congenital viral infections in England over five decades: a population-based observational study.1 passage
• Connecting clusters of COVID-19: an epidemiological and serological investigation.1 passage
• Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries.1 passage
• Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial.1 passage
• Contact precautions in single-bed or multiple-bed rooms for patients with extended-spectrum β-lactamase-producing Enterobacteriaceae in Dutch hospitals: a cluster-randomised, crossover, non-inferiority study.1 passage
• Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial.1 passage
• Correction.1 passage
• Corrections.1 passage
• Corynebacterium ulcerans cutaneous diphtheria.1 passage
• Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.1 passage
• Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.1 passage
• Cost-effectiveness of national mandatory screening of all admissions to English National Health Service hospitals for meticillin-resistant Staphylococcus aureus: a mathematical modelling study.1 passage
• Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.1 passage
• Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.1 passage
• Cost-effectiveness of scaling up mass drug administration for the control of soil-transmitted helminths: a comparison of cost function and constant costs analyses.1 passage
• Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation.1 passage
• Cryptococcal meningoencephalitis: time for action.1 passage
• Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.1 passage
• Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis.1 passage
• Current gaps in sepsis immunology: new opportunities for translational research.1 passage
• DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.1 passage
• Dangers of vaccine refusal near the herd immunity threshold: a modelling study.1 passage
• De-implementation strategy to reduce inappropriate use of intravenous and urinary catheters (RICAT): a multicentre, prospective, interrupted time-series and before and after study.1 passage
• Decarceration and community re-entry in the COVID-19 era.1 passage
• Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.1 passage
• Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.1 passage
• Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial.1 passage
• Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine.1 passage
• Dengue during pregnancy and adverse fetal outcomes: a systematic review and meta-analysis.1 passage
• Dengue: knowledge gaps, unmet needs, and research priorities.1 passage
• Design, recruitment, and microbiological considerations in human challenge studies.1 passage
• Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study.1 passage
• Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study.1 passage
• Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.1 passage
• Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.1 passage
• Development of vaccines against Zika virus.1 passage
• Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.1 passage
• Diagnostic accuracy of loop-mediated isothermal amplification as a near-patient test for meningococcal disease in children: an observational cohort study.1 passage
• Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis.1 passage
• Diagnostic value of imaging in infective endocarditis: a systematic review.1 passage
• Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.1 passage
• Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.1 passage
• Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.1 passage
• Disease X: accelerating the development of medical countermeasures for the next pandemic.1 passage
• Disease and economic burdens of dengue.1 passage
• Disseminated sporotrichosis following iatrogenic immunosuppression for suspected pyoderma gangrenosum.1 passage
• Does antimalarial mass drug administration increase or decrease the risk of resistance?1 passage
• Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.1 passage
• Donate now to prevent sexually transmitted infections later: incentivising testing of sexually transmitted infections.1 passage
• Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study.1 passage
• Drug-resistant tuberculosis in eastern Europe and central Asia: a time-series analysis of routine surveillance data.1 passage
• Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.1 passage
• Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.1 passage
• Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study.1 passage
• Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.1 passage
• Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.1 passage
• Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission.1 passage
• Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring.1 passage
• Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study.1 passage
• Early dynamics of transmission and control of COVID-19: a mathematical modelling study.1 passage
• Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.1 passage
• Early transmission and case fatality of Ebola virus at the index site of the 2013-16 west African Ebola outbreak: a cross-sectional seroprevalence survey.1 passage
• Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.1 passage
• Ebola virus disease: an update on post-exposure prophylaxis.1 passage
• Ebola: lessons learned and future challenges for Europe.1 passage
• Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.1 passage
• Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.1 passage
• Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis.1 passage
• Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.1 passage
• Effect of a conditional cash transfer programme on leprosy treatment adherence and cure in patients from the nationwide 100 Million Brazilian Cohort: a quasi-experimental study.1 passage
• Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis.1 passage
• Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational study.1 passage
• Effect of antibiotic stewardship interventions in primary care on antimicrobial resistance of Escherichia coli bacteraemia in England (2013-18): a quasi-experimental, ecological, data linkage study.1 passage
• Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.1 passage
• Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.1 passage
• Effect of body surface decolonisation on bacteriuria and candiduria in intensive care units: an analysis of a cluster-randomised trial.1 passage
• Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.1 passage
• Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study.1 passage
• Effect of climate change on vector-borne disease risk in the UK.1 passage
• Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study.1 passage
• Effect of laminar airflow ventilation on surgical site infections: a systematic review and meta-analysis.1 passage
• Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis.1 passage
• Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial.1 passage
• Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis.1 passage
• Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study.1 passage
• Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis.1 passage
• Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.1 passage
• Effect of sanitation and water treatment on intestinal protozoa infection: a systematic review and meta-analysis.1 passage
• Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.1 passage
• Effect of the Ebola-virus-disease epidemic on malaria case management in Guinea, 2014: a cross-sectional survey of health facilities.1 passage
• Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study.1 passage
• Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.1 passage
• Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004-18.1 passage
• Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial.1 passage
• Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.1 passage
• Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.1 passage
• Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial.1 passage
• Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study.1 passage
• Effectiveness of a tailored intervention to reduce antibiotics for urinary tract infections in nursing home residents: a cluster, randomised controlled trial.1 passage
• Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.1 passage
• Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study.1 passage
• Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.1 passage
• Effectiveness of insertion and maintenance bundles to prevent central-line-associated bloodstream infections in critically ill patients of all ages: a systematic review and meta-analysis.1 passage
• Effectiveness of interventions for diagnosis and treatment of tuberculosis in hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review.1 passage
• Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study.1 passage
• Effectiveness of national and subnational infection prevention and control interventions in high-income and upper-middle-income countries: a systematic review.1 passage
• Effectiveness of pre-entry active tuberculosis and post-entry latent tuberculosis screening in new entrants to the UK: a retrospective, population-based cohort study.1 passage
• Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection).1 passage
• Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study.1 passage
• Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS).1 passage
• Effects of control interventions on Clostridium difficile infection in England: an observational study.1 passage
• Effects of national antibiotic stewardship and infection control strategies on hospital-associated and community-associated meticillin-resistant Staphylococcus aureus infections across a region of Scotland: a non-linear time-series study.1 passage
• Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.1 passage
• Effects of the Australian National Hand Hygiene Initiative after 8 years on infection control practices, health-care worker education, and clinical outcomes: a longitudinal study.1 passage
• Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial.1 passage
• Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.1 passage
• Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial.1 passage
• Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.1 passage
• Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blind, parallel-group, phase 3, randomised controlled trial.1 passage
• Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.1 passage
• Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial.1 passage
• Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial.1 passage
• Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).1 passage
• Efficacy and safety of oxantel pamoate in school-aged children infected with Trichuris trichiura on Pemba Island, Tanzania: a parallel, randomised, controlled, dose-ranging study.1 passage
• Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial.1 passage
• Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial.1 passage
• Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.1 passage
• Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.1 passage
• Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.1 passage
• Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.1 passage
• Efficacy and safety of tribendimidine against Opisthorchis viverrini: two randomised, parallel-group, single-blind, dose-ranging, phase 2 trials.1 passage
• Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial.1 passage
• Efficacy and safety of tribendimidine, tribendimidine plus ivermectin, tribendimidine plus oxantel pamoate, and albendazole plus oxantel pamoate against hookworm and concomitant soil-transmitted helminth infections in Tanzania and Côte d'Ivoire: a randomised, controlled, single-blinded, non-inferiority trial.1 passage
• Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.1 passage
• Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis.1 passage
• Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial.1 passage
• Efficacy and tolerability of triple drug therapy with albendazole, pyrantel pamoate, and oxantel pamoate compared with albendazole plus oxantel pamoate, pyrantel pamoate plus oxantel pamoate, and mebendazole plus pyrantel pamoate and oxantel pamoate against hookworm infections in school-aged children in Laos: a randomised, single-blind trial.1 passage
• Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.1 passage
• Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.1 passage
• Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials.1 passage
• Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial.1 passage
• Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.1 passage
• Efficacy of topical mosquito repellent (picaridin) plus long-lasting insecticidal nets versus long-lasting insecticidal nets alone for control of malaria: a cluster randomised controlled trial.1 passage
• Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.1 passage
• Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.1 passage
• Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.1 passage
• Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary?1 passage
• Elimination of visceral leishmaniasis on the Indian subcontinent.1 passage
• Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study.1 passage
• Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance data.1 passage
• Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study.1 passage
• Emergence of the Asian lineage of Zika virus in Angola: an outbreak investigation.1 passage
• Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases.1 passage
• Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks.1 passage
• Emerging tick-borne infections in mainland China: an increasing public health threat.1 passage
• Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool.1 passage
• Enhanced performance feedback and patient participation to improve hand hygiene compliance of health-care workers in the setting of established multimodal promotion: a single-centre, cluster randomised controlled trial.1 passage
• Enhancing collaboration between China and African countries for schistosomiasis control.1 passage
• Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality.1 passage
• Epidemic arboviral diseases: priorities for research and public health.1 passage
• Epidemic preparedness: why is there a need to accelerate the development of diagnostics?1 passage
• Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011-17: a prospective observational study.1 passage
• Epidemiological characteristics of an urban plague epidemic in Madagascar, August-November, 2017: an outbreak report.1 passage
• Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study.1 passage
• Epidemiological, clinical, and laboratory characteristics of 48 cases of "Babesia venatorum" infection in China: a descriptive study.1 passage
• Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study.1 passage
• Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series.1 passage
• Epidemiology of common resistant bacterial pathogens in the countries of the Arab League.1 passage
• Epidemiology of varicella among immigrants and non-immigrants in Quebec, Canada, before and after the introduction of childhood varicella vaccination: a retrospective cohort study.1 passage
• Essentials of filoviral load quantification.1 passage
• Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015.1 passage
• Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015.1 passage
• Estimates of the severity of coronavirus disease 2019: a model-based analysis.1 passage
• Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013.1 passage
• Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study.1 passage
• Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.1 passage
• Ethical implications of recruiting universal stool donors for faecal microbiota transplantation.1 passage
• Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study.1 passage
• Evidence for action: a One Health learning platform on interventions to tackle antimicrobial resistance.1 passage
• Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study.1 passage
• Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study.1 passage
• Evolving viral and serological stages of Zika virus RNA-positive blood donors and estimation of incidence of infection during the 2016 Puerto Rican Zika epidemic: an observational cohort study.1 passage
• Excess mortality associated with loiasis: a retrospective population-based cohort study.1 passage
• Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies.1 passage
• Experimental infection of human volunteers.1 passage
• Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.1 passage
• Extended-spectrum β-lactamase-producing Escherichia coli in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study.1 passage
• Extensively drug-resistant tuberculosis in a young child after travel to India.1 passage
• Eye examination for early diagnosis of disseminated tuberculosis in patients with AIDS.1 passage
• Facial Balamuthia mandrillaris infection with neurological involvement in an immunocompetent child.1 passage
• Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study.1 passage
• Familiar barriers still unresolved-a perspective on the Zika virus outbreak research response.1 passage
• Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study.1 passage
• Food for thought: addressing undernutrition to end tuberculosis.1 passage
• Fractional dose compared with standard dose inactivated poliovirus vaccine in children: a systematic review and meta-analysis.1 passage
• Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.1 passage
• From the micro to the macro to improve health: microorganism ecology and society in teaching infectious disease epidemiology.1 passage
• Fungal infections in HIV/AIDS.1 passage
• Future challenges for clinical care of an ageing population infected with HIV: a modelling study.1 passage
• Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial.1 passage
• Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study.1 passage
• Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.1 passage
• Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.1 passage
• Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study.1 passage
• Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study.1 passage
• Genomic evidence for reinfection with SARS-CoV-2: a case study.1 passage
• Genomic-informed pathogen surveillance in Africa: opportunities and challenges.1 passage
• Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.1 passage
• Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data.1 passage
• Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis.1 passage
• Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013.1 passage
• Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.1 passage
• Global burden of drug-resistant tuberculosis in children: a mathematical modelling study.1 passage
• Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling.1 passage
• Global burden of melioidosis in 2015: a systematic review and data synthesis.1 passage
• Global burden of recurrent vulvovaginal candidiasis: a systematic review.1 passage
• Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy.1 passage
• Global emergence of enterovirus D68: a systematic review.1 passage
• Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: a systematic review of individual case data.1 passage
• Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.1 passage
• Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance.1 passage
• Global feasibility assessment of interrupting the transmission of soil-transmitted helminths: a statistical modelling study.1 passage
• Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.1 passage
• Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology.1 passage
• Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM.1 passage
• Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology.1 passage
• Global incidence of serogroup B invasive meningococcal disease: a systematic review.1 passage
• Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study.1 passage
• Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study.1 passage
• Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis.1 passage
• Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study.1 passage
• Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019.1 passage
• Group B streptococcal disease in UK and Irish infants younger than 90 days, 2014-15: a prospective surveillance study.1 passage
• Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis.1 passage
• Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.1 passage
• Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).1 passage
• Guidelines, law, and governance: disconnects in the global control of airline-associated infectious diseases.1 passage
• H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.1 passage
• HIV infection predominantly affecting children in Sindh, Pakistan, 2019: a cross-sectional study of an outbreak.1 passage
• HIV rumbles on in the south of the USA.1 passage
• HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.1 passage
• HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination.1 passage
• Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study.1 passage
• Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review.1 passage
• Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey.1 passage
• Helminths in organ transplantation.1 passage
• Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis.1 passage
• Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.1 passage
• High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial.1 passage
• High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.1 passage
• Highly targeted spatiotemporal interventions against cholera epidemics, 2000-19: a scoping review.1 passage
• Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.1 passage
• Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.1 passage
• Hospital admissions for viral meningitis in children in England over five decades: a population-based observational study.1 passage
• Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus.1 passage
• Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort.1 passage
• Host susceptibility to non-tuberculous mycobacterial infections.1 passage
• Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.1 passage
• Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.1 passage
• Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study.1 passage
• How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review.1 passage
• Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent.1 passage
• Human cyclosporiasis.1 passage
• Human infection with a novel tick-borne Anaplasma species in China: a surveillance study.1 passage
• Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.1 passage
• Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis.1 passage
• Human schistosomiasis in the post mass drug administration era.1 passage
• Human sparganosis, a neglected food borne zoonosis.1 passage
• Human toxocariasis.1 passage
• Hydromorphone and the risk of infective endocarditis among people who inject drugs: a population-based, retrospective cohort study.1 passage
• Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study.1 passage
• Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study.1 passage
• Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.1 passage
• Immunity against diphtheria among children aged 5-17 years in India, 2017-18: a cross-sectional, population-based serosurvey.1 passage
• Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis.1 passage
• Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.1 passage
• Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.1 passage
• Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.1 passage
• Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.1 passage
• Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.1 passage
• Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.1 passage
• Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.1 passage
• Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.1 passage
• Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.1 passage
• Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.1 passage
• Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.1 passage
• Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.1 passage
• Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial.1 passage
• Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.1 passage
• Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.1 passage
• Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.1 passage
• Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.1 passage
• Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.1 passage
• Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial.1 passage
• Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis.1 passage
• Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.1 passage
• Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.1 passage
• Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.1 passage
• Immunotherapeutic approaches to treatment of fungal diseases.1 passage
• Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.1 passage
• Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance.1 passage
• Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.1 passage
• Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.1 passage
• Implications of insecticide resistance for malaria vector control with long-lasting insecticidal nets: a WHO-coordinated, prospective, international, observational cohort study.1 passage
• Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study.1 passage
• Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity.1 passage
• Improvement of fungal disease identification and management: combined health systems and public health approaches.1 passage
• Improving the cascade of global tuberculosis care: moving from the "what" to the "how" of quality improvement.1 passage
• Improving the estimation of the global burden of antimicrobial resistant infections.1 passage
• In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management.1 passage
• Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.1 passage
• Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.1 passage
• Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.1 passage
• Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study.1 passage
• Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis.1 passage
• Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: a multisite prospective longitudinal cohort study.1 passage
• Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey.1 passage
• Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study.1 passage
• India tackles lymphatic filariasis.1 passage
• Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis.1 passage
• Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study.1 passage
• Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method.1 passage
• Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.1 passage
• Infectious causes of microcephaly: epidemiology, pathogenesis, diagnosis, and management.1 passage
• Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.1 passage
• Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis.1 passage
• Innovative tools and approaches to end the transmission of Mycobacterium leprae.1 passage
• Inpatient versus outpatient parenteral antibiotic therapy at home for acute infections in children: a systematic review.1 passage
• Insights from clinical research completed during the west Africa Ebola virus disease epidemic.1 passage
• Institutional trust and misinformation in the response to the 2018-19 Ebola outbreak in North Kivu, DR Congo: a population-based survey.1 passage
• Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.1 passage
• Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study.1 passage
• Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis.1 passage
• Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.1 passage
• Internal migration and transmission dynamics of tuberculosis in Shanghai, China: an epidemiological, spatial, genomic analysis.1 passage
• Interventions to improve oral vaccine performance: a systematic review and meta-analysis.1 passage
• Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study.1 passage
• Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses.1 passage
• Interventions to reduce zoonotic and pandemic risks from avian influenza in Asia.1 passage
• Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis.1 passage
• Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial.1 passage
• Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study.1 passage
• Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study.1 passage
• Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series.1 passage
• Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.1 passage
• Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study.1 passage
• Kissing, saliva exchange, and transmission of Neisseria gonorrhoeae.1 passage
• Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation.1 passage
• Laboratory informatics capacity for effective antimicrobial resistance surveillance in resource-limited settings.1 passage
• Lassa virus circulating in Liberia: a retrospective genomic characterisation.1 passage
• Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study.1 passage
• Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.1 passage
• Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.1 passage
• Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.1 passage
• Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.1 passage
• Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.1 passage
• Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.1 passage
• Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.1 passage
• Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).1 passage
• Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis.1 passage
• Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.1 passage
• Long-term circulation of Zika virus in Thailand: an observational study.1 passage
• Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study.1 passage
• Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community: an interrupted time-series analysis.1 passage
• Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.1 passage
• Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study.1 passage
• Long-term sequelae of West Nile virus-related illness: a systematic review.1 passage
• Long-term survival and cause-specific mortality of patients newly diagnosed with tuberculosis in São Paulo state, Brazil, 2010-15: a population-based, longitudinal study.1 passage
• Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study.1 passage
• Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infection: a prospective cohort study.1 passage
• Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.1 passage
• Making sense of differences in pneumococcal serotype replacement.1 passage
• Malaria elimination in India and regional implications.1 passage
• Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis.1 passage
• Management of Cryptococcus gattii meningoencephalitis.1 passage
• Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).1 passage
• Marseillevirus in lymphoma: a giant in the lymph node.1 passage
• Mass chemoprophylaxis for control of outbreaks of meningococcal disease.1 passage
• Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.1 passage
• Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial.1 passage
• Maternal immunisation to improve the health of HIV-exposed infants.1 passage
• Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.1 passage
• Maternal immunisation: collaborating with mother nature.1 passage
• Maternal immunisation: ethical issues.1 passage
• Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.1 passage
• Measles eradication-retreating is not an option.1 passage
• Measles immunity gaps and the progress towards elimination: a multi-country modelling analysis.1 passage
• Measuring health-care delays among privately insured patients with tuberculosis in the USA: an observational cohort study.1 passage
• Medical countermeasures against henipaviruses: a review and public health perspective.1 passage
• Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment.1 passage
• Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys.1 passage
• Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results.1 passage
• Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment.1 passage
• Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.1 passage
• Menstrual toxic shock syndrome: case report and systematic review of the literature.1 passage
• Microbial evolutionary medicine: from theory to clinical practice.1 passage
• Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission.1 passage
• Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review.1 passage
• Models of gonorrhoea transmission from the mouth and saliva.1 passage
• Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.1 passage
• Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study.1 passage
• Molecular point-of-care testing for chlamydia and gonorrhoea in Indigenous Australians attending remote primary health services (TTANGO): a cluster-randomised, controlled, crossover trial.1 passage
• Molecular surveillance of norovirus, 2005-16: an epidemiological analysis of data collected from the NoroNet network.1 passage
• Monitoring approaches for health-care workers during the COVID-19 pandemic.1 passage
• Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study.1 passage
• Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.1 passage
• Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016.1 passage
• More medicines alone cannot ensure the treatment of neglected tropical diseases.1 passage
• Mortality and adverse joint outcomes following septic arthritis of the native knee: a longitudinal cohort study of patients receiving arthroscopic washout.1 passage
• Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study.1 passage
• Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study.1 passage
• Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis.1 passage
• Mortality related to invasive infections, sepsis, and septic shock in critically ill children in Australia and New Zealand, 2002-13: a multicentre retrospective cohort study.1 passage
• Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study.1 passage
• Multidrug therapy for leprosy: a game changer on the path to elimination.1 passage
• Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey.1 passage
• Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.1 passage
• Mumps in a highly vaccinated Marshallese community in Arkansas, USA: an outbreak report.1 passage
• Mycetoma: a unique neglected tropical disease.1 passage
• Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data.1 passage
• Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial.1 passage
• Nationwide and regional incidence of microbiologically confirmed pulmonary tuberculosis in South Africa, 2004-12: a time series analysis.1 passage
• Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential.1 passage
• Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study.1 passage
• Neglected endemic mycoses.1 passage
• Neonate with Mycoplasma hominis meningoencephalitis given moxifloxacin.1 passage
• Neurocysticercosis-related seizures in the post-partum period: two cases and a review of the literature.1 passage
• New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice.1 passage
• New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective.1 passage
• New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective.1 passage
• New perspectives for preventing hepatitis C virus liver graft infection.1 passage
• New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.1 passage
• New therapeutic agents for chronic hepatitis B.1 passage
• Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study.1 passage
• Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials.1 passage
• Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study.1 passage
• Nurses at the frontline of public health emergency preparedness and response: lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks.1 passage
• Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis.1 passage
• Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.1 passage
• Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.1 passage
• Old and new challenges in Chagas disease.1 passage
• Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.1 passage
• Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial.1 passage
• Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.1 passage
• Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.1 passage
• Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.1 passage
• Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.1 passage
• Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study.1 passage
• Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.1 passage
• Out-of-pocket health expenditures and antimicrobial resistance in low-income and middle-income countries: an economic analysis.1 passage
• Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: a matched case-control study.1 passage
• Outbreak of Neisseria meningitidis serogroup C outside the meningitis belt-Liberia, 2017: an epidemiological and laboratory investigation.1 passage
• Outbreak of Zika virus infection in Singapore: an epidemiological, entomological, virological, and clinical analysis.1 passage
• Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report.1 passage
• Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study.1 passage
• Outbreak of urogenital schistosomiasis in Corsica (France): an epidemiological case study.1 passage
• Outbreak response as an essential component of vaccine development.1 passage
• PCR correction strategies for malaria drug trials: updates and clarifications.1 passage
• PERISCOPE: road towards effective control of pertussis.1 passage
• PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.1 passage
• Para-aminosalicylic acid: the return of an old friend.1 passage
• Pasteurella multocida infection in solid organ transplantation.1 passage
• Pathogens, prejudice, and politics: the role of the global health community in the European refugee crisis.1 passage
• Pay-it-forward gonorrhoea and chlamydia testing among men who have sex with men in China: a randomised controlled trial.1 passage
• Pay-it-forward strategy to enhance uptake of dual gonorrhea and chlamydia testing among men who have sex with men in China: a pragmatic, quasi-experimental study.1 passage
• Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.1 passage
• Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study.1 passage
• Performance and operational feasibility of two diagnostic tests for cryptosporidiosis in children (CRYPTO-POC): a clinical, prospective, diagnostic accuracy study.1 passage
• Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.1 passage
• Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study.1 passage
• Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study.1 passage
• Permutations of time and place in tuberculosis.1 passage
• Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report.1 passage
• Personalised randomised controlled trial designs-a new paradigm to define optimal treatments for carbapenem-resistant infections.1 passage
• Pertussis and influenza immunisation during pregnancy: a landscape review.1 passage
• Photoantimicrobials-are we afraid of the light?1 passage
• Phylogenomic analysis of Neisseria gonorrhoeae transmission to assess sexual mixing and HIV transmission risk in England: a cross-sectional, observational, whole-genome sequencing study.1 passage
• Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.1 passage
• Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study.1 passage
• Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study.1 passage
• Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?1 passage
• Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.1 passage
• Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.1 passage
• Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study.1 passage
• Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers.1 passage
• Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.1 passage
• Post-migration follow-up of migrants identified to be at increased risk of developing tuberculosis at pre-migration screening: a systematic review and meta-analysis.1 passage
• Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study.1 passage
• Potential for Zika virus introduction and transmission in resource-limited countries in Africa and the Asia-Pacific region: a modelling study.1 passage
• Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study.1 passage
• Potential of marine natural products against drug-resistant bacterial infections.1 passage
• Potential of marine natural products against drug-resistant fungal, viral, and parasitic infections.1 passage
• Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?1 passage
• Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study.1 passage
• Predictors of mortality in patients with yellow fever: an observational cohort study.1 passage
• Pregnancy and breastfeeding in the context of Ebola: a systematic review.1 passage
• Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.1 passage
• Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study.1 passage
• Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.1 passage
• Prevalence of abdominal cystic echinococcosis in rural Bulgaria, Romania, and Turkey: a cross-sectional, ultrasound-based, population study from the HERACLES project.1 passage
• Prevalence of and risk factors for active tuberculosis in migrants screened before entry to the UK: a population-based cross-sectional study.1 passage
• Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey.1 passage
• Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study.1 passage
• Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study.1 passage
• Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis.1 passage
• Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study.1 passage
• Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis.1 passage
• Prevalence of scabies and impetigo worldwide: a systematic review.1 passage
• Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.1 passage
• Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study.1 passage
• Prevention and control of dengue-the light at the end of the tunnel.1 passage
• Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial.1 passage
• Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease.1 passage
• Prevention of host-to-host transmission by SARS-CoV-2 vaccines.1 passage
• Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study.1 passage
• Prevention of malaria in pregnancy.1 passage
• Prevention of yellow fever in travellers: an update.1 passage
• Preventive malaria treatment for contacts of patients with Ebola virus disease in the context of the west Africa 2014-15 Ebola virus disease response: an economic analysis.1 passage
• Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial.1 passage
• Primary osteomyelitis caused by hypervirulent Klebsiella pneumoniae.1 passage
• Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.1 passage
• Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study.1 passage
• Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions.1 passage
• Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.1 passage
• Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis.1 passage
• Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial.1 passage
• Protection of the house against Chagas disease, dengue, leishmaniasis, and lymphatic filariasis: a systematic review.1 passage
• Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.1 passage
• Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey.1 passage
• Pulmonary and sinus fungal diseases in non-immunocompromised patients.1 passage
• Pulmonary nodules in African migrants caused by chronic schistosomiasis.1 passage
• Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study.1 passage
• QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.1 passage
• Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.1 passage
• Quantification and interpretation of attributable mortality in core clinical infectious disease journals.1 passage
• Quantifying drivers of antibiotic resistance in humans: a systematic review.1 passage
• Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017.1 passage
• Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017.1 passage
• Quantifying the global number of tuberculosis survivors: a modelling study.1 passage
• Quantifying the rates of late reactivation tuberculosis: a systematic review.1 passage
• Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.1 passage
• Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study.1 passage
• Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.1 passage
• Re-examining causes of surgical site infections following elective surgery in the era of asepsis.1 passage
• Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.1 passage
• Reappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: a systematic review and network meta-analysis of 61 randomised clinical trials.1 passage
• Reassessment of the positive predictive value and specificity of Xpert MTB/RIF: a diagnostic accuracy study in the context of community-wide screening for tuberculosis.1 passage
• Recent successes in therapeutics for Ebola virus disease: no time for complacency.1 passage
• Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study.1 passage
• Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984-2018: an evaluation of Food and Drug Administration flexibilities.1 passage
• Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.1 passage
• Requirements for global elimination of hepatitis B: a modelling study.1 passage
• Researching Zika in pregnancy: lessons for global preparedness.1 passage
• Resistance to hepatitis C virus: potential genetic and immunological determinants.1 passage
• Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.1 passage
• Resurgence of scarlet fever in China: a 13-year population-based surveillance study.1 passage
• Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study.1 passage
• Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.1 passage
• Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.1 passage
• Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.1 passage
• Risk factors associated with revision for prosthetic joint infection after hip replacement: a prospective observational cohort study.1 passage
• Risk factors associated with revision for prosthetic joint infection following knee replacement: an observational cohort study from England and Wales.1 passage
• Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study.1 passage
• Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study.1 passage
• Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.1 passage
• Risk of COVID-19 in health-care workers in Denmark: an observational cohort study.1 passage
• Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.1 passage
• Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study.1 passage
• Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark.1 passage
• Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis.1 passage
• Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis.1 passage
• Rotational thromboelastometry alongside conventional coagulation testing in patients with Crimean-Congo haemorrhagic fever: an observational cohort study.1 passage
• Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study.1 passage
• Routine universal testing versus selective or incidental testing for oropharyngeal Neisseria gonorrhoeae in women in the Netherlands: a retrospective cohort study.1 passage
• SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.1 passage
• SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.1 passage
• SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England.1 passage
• SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.1 passage
• SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series.1 passage
• STROBE-metagenomics: a STROBE extension statement to guide the reporting of metagenomics studies.1 passage
• Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.1 passage
• Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.1 passage
• Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.1 passage
• Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.1 passage
• Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.1 passage
• Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.1 passage
• Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.1 passage
• Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.1 passage
• Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.1 passage
• Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.1 passage
• Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.1 passage
• Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.1 passage
• Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.1 passage
• Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.1 passage
• Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.1 passage
• Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial.1 passage
• Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.1 passage
• Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.1 passage
• Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.1 passage
• Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.1 passage
• Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.1 passage
• Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.1 passage
• Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.1 passage
• Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.1 passage
• Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.1 passage
• Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.1 passage
• Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.1 passage
• Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial.1 passage
• Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.1 passage
• Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.1 passage
• Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.1 passage
• Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.1 passage
• Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.1 passage
• Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.1 passage
• Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.1 passage
• Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.1 passage
• Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.1 passage
• Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.1 passage
• Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.1 passage
• Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study.1 passage
• Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study.1 passage
• Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.1 passage
• Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.1 passage
• Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.1 passage
• Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.1 passage
• Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study.1 passage
• Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.1 passage
• Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.1 passage
• Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis.1 passage
• Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial.1 passage
• Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.1 passage
• Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.1 passage
• Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.1 passage
• Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.1 passage
• Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.1 passage
• Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.1 passage
• Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.1 passage
• Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial.1 passage
• Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes.1 passage
• Scaling up COVID-19 rapid antigen tests: promises and challenges.1 passage
• Schistosomiasis in the first 1000 days.1 passage
• Sensitive diagnostic tools and targeted drug administration strategies are needed to eliminate schistosomiasis.1 passage
• Sepsis: a roadmap for future research.1 passage
• Sequelae of Ebola virus disease: the emergency within the emergency.1 passage
• Serocorrelates of protection against infant group B streptococcus disease.1 passage
• Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study.1 passage
• Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: a multicentre, open-label, randomised, controlled, superiority trial.1 passage
• Serology testing in the COVID-19 pandemic response.1 passage
• Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review.1 passage
• Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study.1 passage
• Severe CNS angiostrongyliasis in a young marine: a case report and literature review.1 passage
• Severe disseminated tuberculosis in HIV-negative refugees.1 passage
• Severe liver fibrosis caused by Schistosoma mansoni: management and treatment with a transjugular intrahepatic portosystemic shunt.1 passage
• Sexually transmitted infections: challenges ahead.1 passage
• Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.1 passage
• Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.1 passage
• Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.1 passage
• Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study.1 passage
• Sociodemographic and geographical inequalities in notifiable infectious diseases in Australia: a retrospective analysis of 21 years of national disease surveillance data.1 passage
• Socioeconomic disparities associated with 29 common infectious diseases in Sweden, 2005-14: an individually matched case-control study.1 passage
• Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial.1 passage
• Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study.1 passage
• Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review.1 passage
• Spatial and temporal distribution of soil-transmitted helminth infection in sub-Saharan Africa: a systematic review and geostatistical meta-analysis.1 passage
• Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis.1 passage
• Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings.1 passage
• Spatiotemporal spread of the 2014 outbreak of Ebola virus disease in Liberia and the effectiveness of non-pharmaceutical interventions: a computational modelling analysis.1 passage
• Spinal epidural abscess caused by Aspergillus spp masquerading as spinal tuberculosis in a person with HIV.1 passage
• Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker.1 passage
• Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015-16: a modelling study.1 passage
• Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.1 passage
• Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis.1 passage
• Strategies to improve detection and management of human parechovirus infection in young infants.1 passage
• Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research.1 passage
• Subacute sclerosing panencephalitis in pregnancy.1 passage
• Subsequent mortality in survivors of Ebola virus disease in Guinea: a nationwide retrospective cohort study.1 passage
• Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.1 passage
• Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK.1 passage
• Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial.1 passage
• Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study.1 passage
• Surveillance for control of antimicrobial resistance.1 passage
• Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.1 passage
• Sustainable access to deworming drugs in a changing landscape.1 passage
• Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study.1 passage
• Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.1 passage
• Symptomatic dengue infection during pregnancy and livebirth outcomes in Brazil, 2007-13: a retrospective observational cohort study.1 passage
• Symptomatic dengue infection during pregnancy and the risk of stillbirth in Brazil, 2006-12: a matched case-control study.1 passage
• Systematic review of antibiotic resistance in acne: an increasing topical and oral threat.1 passage
• T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study.1 passage
• Targeted point-of-care testing compared with syndromic management of urogenital infections in women (WISH): a cross-sectional screening and diagnostic accuracy study.1 passage
• Technical assessment of the neonatal early-onset sepsis risk calculator.1 passage
• Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.1 passage
• Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.1 passage
• Testing the hypothesis that treatment can eliminate HIV: a nationwide, population-based study of the Danish HIV epidemic in men who have sex with men.1 passage
• The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation.1 passage
• The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats.1 passage
• The HIV care continuum in Latin America: challenges and opportunities.1 passage
• The Israeli public health response to wild poliovirus importation.1 passage
• The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later.1 passage
• The Lancet Infectious Diseases HIV Prevention Resource Center.1 passage
• The One Health stewardship of colistin as an antibiotic of last resort for human health in South Africa.1 passage
• The UK's pandemic influenza research portfolio: a model for future research on emerging infections.1 passage
• The WHO public health approach to HIV treatment and care: looking back and looking ahead.1 passage
• The basic reproduction number (R1 passage
• The burden of Legionnaires' disease in New Zealand (LegiNZ): a national surveillance study.1 passage
• The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.1 passage
• The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden.1 passage
• The development of global vaccine stockpiles.1 passage
• The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis.1 passage
• The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study.1 passage
• The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy.1 passage
• The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi.1 passage
• The effect of HIV infection on the host response to bacterial sepsis.1 passage
• The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial in seronegative Indian infants.1 passage
• The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.1 passage
• The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.1 passage
• The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.1 passage
• The effect of global change on mosquito-borne disease.1 passage
• The effect of heterogeneity in uptake of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling study.1 passage
• The effects of antibiotic cycling and mixing on antibiotic resistance in intensive care units: a cluster-randomised crossover trial.1 passage
• The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review.1 passage
• The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study.1 passage
• The evolving research agenda for paediatric tuberculosis infection.1 passage
• The expanding role of co-trimoxazole in developing countries.1 passage
• The eyes have it: influenza virus infection beyond the respiratory tract.1 passage
• The forgotten tale of Brazilian phage therapy.1 passage
• The future role of CD4 cell count for monitoring antiretroviral therapy.1 passage
• The geography of imported malaria to non-endemic countries: a meta-analysis of nationally reported statistics.1 passage
• The global burden of dengue: an analysis from the Global Burden of Disease Study 2013.1 passage
• The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017.1 passage
• The global burden of scabies: a cross-sectional analysis from the Global Burden of Disease Study 2015.1 passage
• The global burden of tuberculosis: results from the Global Burden of Disease Study 2015.1 passage
• The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017.1 passage
• The global economic burden of dengue: a systematic analysis.1 passage
• The global incidence and diagnosis of fungal keratitis.1 passage
• The global problem of antifungal resistance: prevalence, mechanisms, and management.1 passage
• The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.1 passage
• The importance of enterovirus surveillance in a post-polio world.1 passage
• The importance of understanding the infectious microenvironment.1 passage
• The number of privately treated tuberculosis cases in India: an estimation from drug sales data.1 passage
• The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study.1 passage
• The potential effect of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling study.1 passage
• The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.1 passage
• The public health crisis of underimmunisation: a global plan of action.1 passage
• The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.1 passage
• The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans.1 passage
• The scientific and ethical feasibility of immunity passports.1 passage
• The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study.1 passage
• The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study.1 passage
• The state of vaccine safety science: systematic reviews of the evidence.1 passage
• The status of tuberculosis vaccine development.1 passage
• The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries.1 passage
• The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study.1 passage
• The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study.1 passage
• The transmission of Mycobacterium tuberculosis in high burden settings.1 passage
• The urgent need for metallo-β-lactamase inhibitors: an unattended global threat.1 passage
• Threats to polio eradication in high-conflict areas in Pakistan and Nigeria: a polling study of caregivers of children younger than 5 years.1 passage
• Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study.1 passage
• Timing of surgical antimicrobial prophylaxis: a phase 3 randomised controlled trial.1 passage
• To give or not to give antibiotics is not the only question.1 passage
• Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial.1 passage
• Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.1 passage
• Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2.1 passage
• Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.1 passage
• Tracking spending on malaria by source in 106 countries, 2000-16: an economic modelling study.1 passage
• Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000-17: a financial modelling study.1 passage
• Transcriptomic signatures for diagnosing tuberculosis in clinical practice: a prospective, multicentre cohort study.1 passage
• Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study.1 passage
• Transmission of Staphylococcus aureus between health-care workers, the environment, and patients in an intensive care unit: a longitudinal cohort study based on whole-genome sequencing.1 passage
• Transmission of drug-resistant tuberculosis in HIV-endemic settings.1 passage
• Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation.1 passage
• Travel-associated infection presenting in Europe (2008-12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation.1 passage
• Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial.1 passage
• Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.1 passage
• Treatment of disseminated nocardiosis: a host-pathogen approach with adjuvant interferon gamma.1 passage
• Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.1 passage
• Treatment of uncomplicated and severe malaria during pregnancy.1 passage
• Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study.1 passage
• Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998-2016: a study of electronic health records.1 passage
• Treponema pallidum detection in lesion and non-lesion sites in men who have sex with men with early syphilis: a prospective, cross-sectional study.1 passage
• Triclosan-containing sutures versus ordinary sutures for reducing surgical site infections in children: a double-blind, randomised controlled trial.1 passage
• Tropheryma whipplei infection and Whipple's disease.1 passage
• Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis.1 passage
• Tuberculosis susceptibility and protection in children.1 passage
• Tuberculosis, HIV, and viral hepatitis diagnostics in eastern Europe and central Asia: high time for integrated and people-centred services.1 passage
• Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.1 passage
• Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.1 passage
• Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.1 passage
• Tularaemia: clinical aspects in Europe.1 passage
• Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance.1 passage
• Understanding threats to polio vaccine commitment among caregivers in high-priority areas of Afghanistan: a polling study.1 passage
• Unexpected outbreaks of arbovirus infections: lessons learned from the Pacific and tropical America.1 passage
• Urgent challenges in implementing live attenuated influenza vaccine.1 passage
• Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.1 passage
• Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance.1 passage
• Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.1 passage
• Use of standardised patients to assess antibiotic dispensing for tuberculosis by pharmacies in urban India: a cross-sectional study.1 passage
• Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study.1 passage
• Using observational data to quantify bias of traveller-derived COVID-19 prevalence estimates in Wuhan, China.1 passage
• Utility of broad-spectrum antibiotics for diagnosing pulmonary tuberculosis in adults: a systematic review and meta-analysis.1 passage
• Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?1 passage
• Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.1 passage
• Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7).1 passage
• Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial.1 passage
• Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7).1 passage
• Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.1 passage
• Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.1 passage
• Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.1 passage
• Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.1 passage
• Vaccinology: time to change the paradigm?1 passage
• Validating clinical practice guidelines for the management of children with non-blanching rashes in the UK (PiC): a prospective, multicentre cohort study.1 passage
• Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies.1 passage
• Venezuela's humanitarian crisis, resurgence of vector-borne diseases, and implications for spillover in the region.1 passage
• Vertebral alveolar echinococcosis-a case report, systematic analysis, and review of the literature.1 passage
• Vertical transmission of Zika virus and its outcomes: a Bayesian synthesis of prospective studies.1 passage
• Viraemia and Ebola virus secretion in survivors of Ebola virus disease in Sierra Leone: a cross-sectional cohort study.1 passage
• WHO international standard for anti-rubella: learning from its application.1 passage
• What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.1 passage
• Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study.1 passage
• Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae: an observational study.1 passage
• Why we should stop using the word leprosy.1 passage
• Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.1 passage
• Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study.1 passage
• Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study.1 passage
• Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial.1 passage
• Zika virus RNA and IgM persistence in blood compartments and body fluids: a prospective observational study.1 passage
• Zika virus in French Polynesia 2013-14: anatomy of a completed outbreak.1 passage
• Zoonotic causes of febrile illness in malaria endemic countries: a systematic review.1 passage
• Zoonotic spillover infections with Borna disease virus 1 leading to fatal human encephalitis, 1999-2019: an epidemiological investigation.1 passage
• Zoonotic tuberculosis in human beings caused by Mycobacterium bovis-a call for action.1 passage
• β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?1 passage